OBJECTIVE: Pathological findings in neonatal brain injury associated with preterm birth include focal and/or diffuse white matter injury (WMI). Despite the heterogeneous nature of this condition, reactive astrogliosis and microgliosis are frequently observed. Thus, molecular mechanisms by which glia activation contribute to WMI were investigated. METHODS: Postmortem brains of neonatal brain injury were investigated to identify molecular features of reactive astrocytes. The contribution of astrogliosis to WMI was further tested in a mouse model in genetically engineered mice. RESULTS: Activated STAT3 signaling in reactive astrocytes was found to be a common feature in postmortem brains of neonatal brain injury. In a mouse model of neonatal WMI, conditional deletion of STAT3 in astrocytes resulted in exacerbated WMI, which was associated with delayed maturation of oligodendrocytes. Mechanistically, the delay occurred in association with overexpression of transforming growth factor (TGF)β-1 in microglia, which in healthy controls decreased with myelin maturation in an age-dependent manner. TGFβ-1 directly and dose-dependently inhibited the maturation of purified oligodendrocyte progenitors, and pharmacological inhibition of TGFβ-1 signaling in vivo reversed the delay in myelin development. Factors secreted from STAT3-deficient astrocytes promoted elevated TGFβ-1 production in cultured microglia compared to wild-type astrocytes. INTERPRETATION: These results suggest that myelin development is regulated by a mechanism involving crosstalk between microglia and oligodendrocyte progenitors. Reactive astrocytes may modify this signaling in a STAT3-dependent manner, preventing the pathological expression of TGFβ-1 in microglia and the impairment of oligodendrocyte maturation.
OBJECTIVE: Pathological findings in neonatal brain injury associated with preterm birth include focal and/or diffuse white matter injury (WMI). Despite the heterogeneous nature of this condition, reactive astrogliosis and microgliosis are frequently observed. Thus, molecular mechanisms by which glia activation contribute to WMI were investigated. METHODS: Postmortem brains of neonatal brain injury were investigated to identify molecular features of reactive astrocytes. The contribution of astrogliosis to WMI was further tested in a mouse model in genetically engineered mice. RESULTS: Activated STAT3 signaling in reactive astrocytes was found to be a common feature in postmortem brains of neonatal brain injury. In a mouse model of neonatal WMI, conditional deletion of STAT3 in astrocytes resulted in exacerbated WMI, which was associated with delayed maturation of oligodendrocytes. Mechanistically, the delay occurred in association with overexpression of transforming growth factor (TGF)β-1 in microglia, which in healthy controls decreased with myelin maturation in an age-dependent manner. TGFβ-1 directly and dose-dependently inhibited the maturation of purified oligodendrocyte progenitors, and pharmacological inhibition of TGFβ-1 signaling in vivo reversed the delay in myelin development. Factors secreted from STAT3-deficient astrocytes promoted elevated TGFβ-1 production in cultured microglia compared to wild-type astrocytes. INTERPRETATION: These results suggest that myelin development is regulated by a mechanism involving crosstalk between microglia and oligodendrocyte progenitors. Reactive astrocytes may modify this signaling in a STAT3-dependent manner, preventing the pathological expression of TGFβ-1 in microglia and the impairment of oligodendrocyte maturation.
Authors: Theodore A Sarafian; Cindy Montes; Tetsuya Imura; Jingwei Qi; Giovanni Coppola; Daniel H Geschwind; Michael V Sofroniew Journal: PLoS One Date: 2010-03-10 Impact factor: 3.240
Authors: Manjeet K Paintlia; Ajaib S Paintlia; Miguel A Contreras; Inderjit Singh; Avtar K Singh Journal: Exp Neurol Date: 2007-12-23 Impact factor: 5.330
Authors: Andrew Craig; Ning Ling Luo; Douglas J Beardsley; Nasiema Wingate-Pearse; David W Walker; A Roger Hohimer; Stephen A Back Journal: Exp Neurol Date: 2003-06 Impact factor: 5.330
Authors: Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill Journal: Mol Pharmacol Date: 2002-07 Impact factor: 4.436
Authors: Enza Lonardo; Patrick C Hermann; Maria-Theresa Mueller; Stephan Huber; Anamaria Balic; Irene Miranda-Lorenzo; Sladjana Zagorac; Sonia Alcala; Iker Rodriguez-Arabaolaza; Juan Carlos Ramirez; Raul Torres-Ruíz; Elena Garcia; Manuel Hidalgo; David Álvaro Cebrián; Rainer Heuchel; Matthias Löhr; Frank Berger; Peter Bartenstein; Alexandra Aicher; Christopher Heeschen Journal: Cell Stem Cell Date: 2011-11-04 Impact factor: 24.633
Authors: Vann Chau; Rollin Brant; Kenneth J Poskitt; Emily W Y Tam; Anne Synnes; Steven P Miller Journal: Pediatr Res Date: 2012-01-25 Impact factor: 3.756
Authors: Brian H Kim; Mariano Guardia Clausi; Michelle Frondelli; Israel C Nnah; Chaitali Saqcena; Radek Dobrowolski; Steven W Levison Journal: Dev Neurosci Date: 2017-06-20 Impact factor: 2.984
Authors: Zhongwen Gao; Qingsan Zhu; Yiping Zhang; Yingzheng Zhao; Lu Cai; Christopher B Shields; Jun Cai Journal: Mol Neurobiol Date: 2013-04-24 Impact factor: 5.590